Sacubitril valsartan

Sacubitril valsartan is a combination medication used to treat heart failure with reduced ejection fraction (HFrEF). Sacubitril is a neprilysin inhibitor that increases levels of beneficial natriuretic peptides, promoting vasodilation and fluid excretion, while valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure and reduces strain on the heart. Together, they improve heart function, reduce hospitalizations, and lower the risk of cardiovascular death in heart failure patients. It is marketed under the brand name Entresto. Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include L-Valine, N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1, 1′-biphenyl]-4-yl]methyl]-, compd. with alpha-ethyl (alphaR, gammaS)-gamma-[(3-carboxy-1-oxopropyl)amino]-alpha-methyl[1 and 1′-biphenyl]-4-pentanoate (1:1). Its PubChem CID is 24755620.

CAS No 1360873-85-3
Molecular Formula C48H58N6O8
Molecular Weight 847.0 g/mol
Synonyms 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid

Frequently Asked Questions